Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rajesh Krishna

Showing results (51-60 of 97) with videos related to

Pageof 10
Sort By:
Clinical Pharmacology in Drug Development|November 2, 2020
Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed-Dose Combination Tablets to Canadian-Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed StatesVikas Kumar Dawra, Kathleen Pelletier, Kyle Matschke, et al.
Biopharmaceutics & Drug Disposition|March 14, 2002
Disposition of radiolabeled BMS-204352 in rats and dogsRajesh Krishna, Ming Yao, Nuggehally R Srinivas, et al.
Journal of Clinical Pharmacology|October 1, 2010
Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug developmentJeffrey D Wetherington, Marc Pfister, Christopher Banfield, et al.
British Journal of Clinical Pharmacology|June 26, 2009
Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjectsRajesh Krishna, Amit Garg, Bo Jin, et al.
The Journal of Pharmacy and Pharmacology|June 25, 2002
Clearance and disposition of indometacin in chronically instrumented fetal lambs following a 3-day continuous intravenous infusionRajesh Krishna, K Wayne Riggs, Eddie Kwan, et al.
Journal of Biopharmaceutical Statistics|December 16, 2022
Use of pharmacodynamic modeling for Bayesian information borrowing in pediatric clinical trialsBernard Sebastien, S Y Amy Cheung, Solange Corriol-Rohou, et al.
Clinical Pharmacology in Drug Development|April 2, 2019
Pharmacokinetic Properties of Single and Multiple Doses of Ertugliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese SubjectsYinhua Li, Yuting Mu, Haihong Shi, et al.
Schizophrenia Research. Cognition|January 8, 2026
Cognitive functioning and hyperhomocysteinemia in schizophreniaUshasti Sinha, Shambhavi Shiva, Anirudh Rajan, et al.
Biopharmaceutics & Drug Disposition|October 6, 2016
Efavirenz does not meaningfully affect the single dose pharmacokinetics of 1200 mg raltegravirRajesh Krishna, Lilly East, Patrick Larson, et al.
Journal of Clinical Pharmacology|August 22, 2014
Non-obligatory role of prostaglandin D2 receptor subtype 1 in rosacea: laropiprant in comparison to a placebo did not alleviate the symptoms of erythematoelangiectaic rosaceaRajesh Krishna, Ying Guo, Valerie Schulz, et al.
Pageof 10

Showing results (51-60 of 97) with videos related to

Sort By:
Pageof 10
Clinical Pharmacology in Drug Development|November 2, 2020
Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed-Dose Combination Tablets to Canadian-Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed StatesVikas Kumar Dawra, Kathleen Pelletier, Kyle Matschke, et al.
Biopharmaceutics & Drug Disposition|March 14, 2002
Disposition of radiolabeled BMS-204352 in rats and dogsRajesh Krishna, Ming Yao, Nuggehally R Srinivas, et al.
Journal of Clinical Pharmacology|October 1, 2010
Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug developmentJeffrey D Wetherington, Marc Pfister, Christopher Banfield, et al.
British Journal of Clinical Pharmacology|June 26, 2009
Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjectsRajesh Krishna, Amit Garg, Bo Jin, et al.
The Journal of Pharmacy and Pharmacology|June 25, 2002
Clearance and disposition of indometacin in chronically instrumented fetal lambs following a 3-day continuous intravenous infusionRajesh Krishna, K Wayne Riggs, Eddie Kwan, et al.
Journal of Biopharmaceutical Statistics|December 16, 2022
Use of pharmacodynamic modeling for Bayesian information borrowing in pediatric clinical trialsBernard Sebastien, S Y Amy Cheung, Solange Corriol-Rohou, et al.
Clinical Pharmacology in Drug Development|April 2, 2019
Pharmacokinetic Properties of Single and Multiple Doses of Ertugliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese SubjectsYinhua Li, Yuting Mu, Haihong Shi, et al.
Schizophrenia Research. Cognition|January 8, 2026
Cognitive functioning and hyperhomocysteinemia in schizophreniaUshasti Sinha, Shambhavi Shiva, Anirudh Rajan, et al.
Biopharmaceutics & Drug Disposition|October 6, 2016
Efavirenz does not meaningfully affect the single dose pharmacokinetics of 1200 mg raltegravirRajesh Krishna, Lilly East, Patrick Larson, et al.
Journal of Clinical Pharmacology|August 22, 2014
Non-obligatory role of prostaglandin D2 receptor subtype 1 in rosacea: laropiprant in comparison to a placebo did not alleviate the symptoms of erythematoelangiectaic rosaceaRajesh Krishna, Ying Guo, Valerie Schulz, et al.
Pageof 10